Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Family Medicine | Geriatrics | Hematology | Internal Medicine | Oncology | Pediatrics | Journal

Back to Journal Articles

Regimen Improves Survival in Childhood Leukemia

Last Updated: September 11, 2009.

 

Dexamethasone-based treatment particularly improves survival for high-risk patients

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
A dexamethasone-based chemotherapy regimen improves survival in children with acute lymphoblastic leukemia without cranial irradiation or some routinely used chemotherapy drugs, according to a study published online Sept. 10 in The Lancet Oncology.

FRIDAY, Sept. 11 (HealthDay News) -- A dexamethasone-based chemotherapy regimen improves survival in children with acute lymphoblastic leukemia (ALL) without cranial irradiation or some routinely used chemotherapy drugs, according to a study published online Sept. 10 in The Lancet Oncology.

Anjo J. Veerman, Ph.D., from VU University Medical Centre in Amsterdam, Netherlands, and colleagues categorized 859 patients (up to 18 years of age) with ALL as high-risk (30 percent) and non-high-risk (70 percent) based on clinical criteria. Non-high-risk patients received a dexamethasone-based three-drug induction followed by medium-dose methotrexate and then maintenance therapy, while high-risk patients received a dexamethasone-based four-drug induction followed by high-dose methotrexate and two intensification courses before receiving maintenance therapy.

The researchers found that 98.5 percent of the non-high-risk group and 96.9 percent of the high-risk group achieved complete remission. After a median follow-up of 72.2 months (excluding the nine patients who died during induction), overall five-year event-free survival was 81 percent in all patients, 84 percent in the non-high-risk group and 72 percent in the high-risk group.

"The overall results of the dexamethasone-based Dutch Childhood Oncology Group ALL-9 protocol are better than those of our previous Berlin-Frankfurt-Munster-based protocols ALL-7 and ALL-8," Veerman and colleagues conclude. "The results for non-high-risk patients were achieved with high cumulative doses of dexamethasone and vincristine, but without the use of anthracyclines, etoposide, cyclophosphamide, or cranial irradiation, therefore minimizing the risk of side effects."

Abstract
Full Text (subscription or payment may be required)

Copyright © 2009 ScoutNews, LLC. All rights reserved.


Previous: Perineural Invasion Points to Colorectal Cancer Outcomes Next: Quick Stenting Beneficial in Heart Attacks in Remote Areas

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.